A Randomized Controlled Open-Label Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Brief description of study

This trial is being done to see whether Cemiplimab in combination with RP1 can reduce the size of your tumor(s) better than Cemiplimab alone, by helping the immune system destroy the tumor(s). The trial is also being done to obtain information on the safety of Cemiplimab in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Clinical Study Identifier: s19-00585
ClinicalTrials.gov Identifier: NCT04050436
Principal Investigator: Janice Mehnert.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.